Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Skinbiotherapeutics Plc LSE:SBTX London Ordinary Share GB00BF33H870 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  4.50 6.92% 69.50 344,642 12:59:23
Bid Price Offer Price High Price Low Price Open Price
69.00 70.00 70.00 65.00 65.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.62 -1.17 108
Last Trade Time Trade Type Trade Size Trade Price Currency
13:02:40 O 5,723 69.80 GBX

Skinbiotherapeutics (SBTX) Latest News

More Skinbiotherapeutics News
Skinbiotherapeutics Investors    Skinbiotherapeutics Takeover Rumours

Skinbiotherapeutics (SBTX) Discussions and Chat

Skinbiotherapeutics (SBTX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
12:02:4169.805,7233,994.65O
11:57:3670.451,399985.60O
11:56:1969.201,000692.00O
11:55:2769.327,5005,199.00O
11:55:2669.327,5005,199.00O
View all Skinbiotherapeutics trades in real-time

Skinbiotherapeutics (SBTX) Top Chat Posts

DateSubject
15/4/2021
09:20
Skinbiotherapeutics Daily Update: Skinbiotherapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SBTX. The last closing price for Skinbiotherapeutics was 65p.
Skinbiotherapeutics Plc has a 4 week average price of 43.75p and a 12 week average price of 29.25p.
The 1 year high share price is 72p while the 1 year low share price is currently 7.58p.
There are currently 155,889,922 shares in issue and the average daily traded volume is 1,695,361 shares. The market capitalisation of Skinbiotherapeutics Plc is £109,122,945.40.
12/4/2021
15:29
jansky61: For all the toing and froing about it there is is still one unarguable fact; despite COVID and a turbulent stock market and all the thousands of posts on these BBs over a period of one year the OPTI share price has stagnated and SBTX has nearly 10 bagged. I'm not saying this can't change but at the moment facts speak louder than words.
12/4/2021
10:14
belgrano2: very sound reasoning blah blah, however I think one major point to consider is risk. OPTI clearly with multiple international deals and started revenue streams with trickle of incoming royalties makes it a much safer investment at current price. opti- 50p share m/cap 44M but 25% of SBTX at current 0.67p a share price worth £26,297,500, off M/C giving £17,702500 or 0.20p a share. So OPTI is currently bloody good value. Throw into the pot, poor market sentiment for OPTI, due to reasons we all know, and we have an artificially depressed share price (for the time being), as better short term opportunities are seen elsewhere. Thought I'd throw this is to add balance to great discussion.
12/4/2021
09:48
blah blah: Crazy? Arguably. However Skin has study results coming potentially followed closely by commercial launch that could justify a big increase in the share price even from here. It also has blue sky ahead of it in terms of share price, and will attract momentum investors. It could run a long way yet. Opti on the other hand has lots of stale bulls invested who will look to exit as the price rises, so lots of resistance, plus no catalysts in terms of what will move the price that I am aware of. So on balance I would still prefer to run this position than switch it to OPTI.
20/3/2021
12:38
aquaesulis01: starty not so sure that OPTI is two years away and already warrants a re-rate in my book. On 15th Dec following elric's excellent interview with Stuart and the price of skinbio languished at 15.625p I posted this on the skinbio LSE BB "Huge ty for that interview elrico, great questions and if any shareholder isn't excited by what is happening in 2021 then they haven't got a pulse! A MUST listen for all shareholders. Based on the potential of 30000 initially company limited number of psoriasis customers at circa £28 per month = £840K per month revenue commencing q3/q4 2021 from just one product, skinbiotix and with 8m active registered National Psoriasis Association members in the USA alone, just imagine the revenues following scale-up. Then we have the prospect of commercialisation of the Croda VIP customers in 2021 as well and the Market Cap is a mere £24/£25 million at today's sp" Now in advance of any study results being released, nothing has changed and yet the skinbio share price has gone up 3.5 times whilst at that time Opti's price was around the 52p mark and hasn't changed at all despite the substantial value of their skinbio investment rocketing; this alone warrants a substantial re-rate of the Opti share price Now throw in the obvious momentum behind sweetbiotix which sounds like an equivalent of the CRODA "Beauty Parade" to me and could happen a lot sooner than people think, so why shouldn't opti treble in price in the not too distant future? "There has been good progress of the Company's manufacturing partner who are in the process of manufacturing an initial run of two metric tonnes of SweetBiotix®. This will be the first industrial scale manufacture of SweetBiotix® products. The manufacturing scale up of SweetBiotix® is being paralleled by the release of a number of independent peer reviewed publications demonstrating prebiotic activity and superior taste profile and open innovation application development with global partners."
18/3/2021
14:51
trotterstrading: One of the biggest criticisms levelled at OPTI is not raising cash to accelerate growth when the share price was north of £1! It was a mistake that has set OPTI back 18Months or more IMO. Selling a few SBTX now while the share price 500% above IPO is completely sensible
15/3/2021
07:27
colinzeal: An objective and well-written report, as is normal for SBTX. Whatever will happen to the share price will happen - no-one can say that they’re not fully updated and informed.
14/3/2021
09:22
jansky61: Slarty and Gary.......... I have a big holding here. It's a bit smaller than it was solely due to my training in 40+ years working in stockbroking i.e. never let an individual share become more than 10% of a portfolio. With the last fortnight's rise my holding in SBTX now constitutes 18% of my SIPP so I'm breaking my own golden rule. Where I slightly disagree is that I don't think the Company is getting ahead of itself but I do believe the market may be getting ahead of the Company. My interpretation of what Gary is saying is simply let us not make the same mistake as we did with OPTI; it doubled from the just over 60p to 130p in two months in mid 2018 and then collapsed back to the original price three months later. I'm not suggesting the same could happen here as the markets and products are entirely different, the only connection is the word "microbiome". I also still believe SBTX is far closer to "commercial traction" than OPTI. What I'm saying in my sometimes long-winded way 🤣 is never forget the stock market; there will be further volatility here justifiable or not. There could well be further buying on all the hype tomorrow morning taking the price to say 60p; there will then be lots of traders taking it all the way back down again. With due deference to Uncle Albert "During the mid 1980s" when those of you who remember it whispered about shares to your mate Sid those new investors who didn't get up in the mornings and bought their shares at 9:30am couldn't believe thy had lost money when they looked again three days later. Those of here are generally more "sophisticated" investors but we don't control market nuances. I may not approve of the old AIM blame game as such but it's not going away. Good Sunday all, it's a beautiful day in South-West London so I'm off to do approx 14000 steps around a well worn path.
12/3/2021
12:14
bernieboy: Gotta be honest, I didn't think we would see the day that SBTX share price would be higher than opti but we are almost there.
10/3/2021
14:25
tonyevo256: This Sheedy guy is some little kid that pretends to be a professional investor. He shorts a stock and then creates fictional avatars to talk the share price down. Inevitably it never works and always ends up losing money. He shorted sbtx at 29p.. you get the picture. Think sociobull$hiter...
17/2/2021
17:10
elrico: I told you so. 😎 I did say buying pressure would resume around the 35/36p mark. OK, it's early and I was expecting this tomorrow, not today. This appears to be the point where the savvier investors are accumulating their holding ahead of the big price pinch which can't be too far away. Yes, I get some people will want to try their hand at trading the range banking on no updates for 4/8 weeks or even longer if the assumption is SBTX will wait for the paper to be written up (2 weeks I believe it may take). Here is the risk...the assumption is the company will NOT offer any further updates on how the psoriasis probiotic is fairing with the first cohorts and or the second cohorts. The company didn't need to RNS today's information because it was widely anticipated...what does this tell you? Some seem to be gambling no further commercial news will fall within the period the human study is taking place. I am betting there will, but relaxed if there isn't. Nobby, I had you pegged as one of the more intelligent investor's. You are more familiar with human studies due to your extensive pharma background. Yet, you seem to miss a major point, that or I am misunderstanding your case to Slarty? Let's be clear; SBTX will have psoriasis products come what may. They know it works because all the science said it will be based on the science paper on the probiotics Winclove has selected. The study is about efficiency not will it or won't it. It is not a pharma phase 3 binary outcome. My conversation with Stuart made this clear, he also said there will likely be more than a single formulation because of the gut flora. I would also remind you Stuart also said the USA base psoriasis association are willing to run with their data. What do you imagine they mean? Moreover, Stuart talks of 500,000 subscriptions per day, not PA. I know he is speaking with numerous psoriasis associations, I thus wager he has figures from them which offer him some confidence in the future. 25,000 baseline subscriptions are worth £9.1m pa, you do the maths on any figure that floats your boat and then add the worlds first antiaging cosmetic backed by science and not smoke & mirrors marketing we have become accustomed too. This will shake up the market. The initial target is 10% of matryxl which is £25m pa. OPTI will benefit greatly from this, that can not be in doubt. You can't ignore 25% of SBTX on its books for too much longer. Another mistake you seem to be making is SBTX is too far behind OPTI in terms of revenues. I will predict greater visibility will trump hope and this is where some investors are looking. Stuart has given us numbers we can work with, SOH has not. This is the point investors are making to me when they ask me if the numbers on the blog are BS or not? There are not BS, I do not BS people. Revisit hTTps://soundcloud.com/user-957798193-127487236/stuart-ashman-ceo?in=user-957798193-127487236/sets/skinbiotherapeutics-podcasts hTTps://lemminginvestors.blogspot.com/2021/01/skinbiotherapeutics-unlocking.html hTTps://lemminginvestors.blogspot.com/2021/02/skinbiotherapeutics-do-not-lose-focus.html
Skinbiotherapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
SBTX
Skinbiothe..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210415 12:22:15